Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 2Recurrence 1Overweight 1Osteoporosis 1Obesity 1Neoplasms 1Myocardial Ischemia 1Heart Diseases 1Endometrial Hyperplasia 1Coronary Disease 1Colonic Neoplasms 1Cardiovascular Diseases 1Breast Neoplasms 1Bone Diseases 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Estrogen Replacement Therapy × Clear all
NCT03077698 2022-06-07

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Xenetic Biosciences, Inc.

Phase 2 Terminated
25 enrolled 14 charts
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡